A Phase II Randomized Trial of Lenvatinib Combined With Letrozole Versus Fulvestrant in Metastatic Estrogen Receptor (ER) Positive, HER2 Negative Breast Cancer, Who Have Progressed on First-line Aromatase Inhibitor + a CDK4/6 Inhibitor
Latest Information Update: 20 Apr 2023
At a glance
- Drugs Lenvatinib (Primary) ; Letrozole (Primary) ; Fulvestrant
- Indications Advanced breast cancer; Carcinoma; HER2 negative breast cancer
- Focus Therapeutic Use
Most Recent Events
- 20 Apr 2023 Last checked against ClinicalTrials.gov: US National Institutes of Health record
- 16 Apr 2023 Status changed from not yet recruiting to recruiting.
- 12 Jan 2022 New trial record